Literature DB >> 34175022

Chronic kidney disease.

Kamyar Kalantar-Zadeh1, Tazeen H Jafar2, Dorothea Nitsch3, Brendon L Neuen4, Vlado Perkovic5.   

Abstract

Chronic kidney disease is a progressive disease with no cure and high morbidity and mortality that occurs commonly in the general adult population, especially in people with diabetes and hypertension. Preservation of kidney function can improve outcomes and can be achieved through non-pharmacological strategies (eg, dietary and lifestyle adjustments) and chronic kidney disease-targeted and kidney disease-specific pharmacological interventions. A plant-dominant, low-protein, and low-salt diet might help to mitigate glomerular hyperfiltration and preserve renal function for longer, possibly while also leading to favourable alterations in acid-base homoeostasis and in the gut microbiome. Pharmacotherapies that alter intrarenal haemodynamics (eg, renin-angiotensin-aldosterone pathway modulators and SGLT2 [SLC5A2] inhibitors) can preserve kidney function by reducing intraglomerular pressure independently of blood pressure and glucose control, whereas other novel agents (eg, non-steroidal mineralocorticoid receptor antagonists) might protect the kidney through anti-inflammatory or antifibrotic mechanisms. Some glomerular and cystic kidney diseases might benefit from disease-specific therapies. Managing chronic kidney disease-associated cardiovascular risk, minimising the risk of infection, and preventing acute kidney injury are crucial interventions for these patients, given the high burden of complications, associated morbidity and mortality, and the role of non-conventional risk factors in chronic kidney disease. When renal replacement therapy becomes inevitable, an incremental transition to dialysis can be considered and has been proposed to possibly preserve residual kidney function longer. There are similarities and distinctions between kidney-preserving care and supportive care. Additional studies of dietary and pharmacological interventions and development of innovative strategies are necessary to ensure optimal kidney-preserving care and to achieve greater longevity and better health-related quality of life for these patients.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 34175022     DOI: 10.1016/S0140-6736(21)00519-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  61 in total

1.  Artemether attenuates renal tubular injury by targeting mitochondria in adriamycin nephropathy mice.

Authors:  Xinyuan Cheng; Peng Zhou; Wenci Weng; Zhijian Sun; Honghong Liu; Yinghui Chen; Yuchun Cai; Xuewen Yu; Taifen Wang; Mumin Shao; Wuyong Yi; Tiegang Yi; Huili Sun; Pengxun Han
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Low-protein diet is inversely related to the incidence of chronic kidney disease in middle-aged and older adults: results from a community-based prospective cohort study.

Authors:  Yu-Jin Kwon; Kyongmin Park; Jun-Hyuk Lee
Journal:  Eur J Nutr       Date:  2022-08-10       Impact factor: 4.865

3.  Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease.

Authors:  Yan-Ni Wang; Zhi-Hao Zhang; Hong-Jiao Liu; Zhi-Yuan Guo; Liang Zou; Ya-Mei Zhang; Ying-Yong Zhao
Journal:  Acta Pharmacol Sin       Date:  2022-08-03       Impact factor: 7.169

4.  Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension.

Authors:  Nian Cao; Cong Lan; Caiyu Chen; Zaicheng Xu; Hao Luo; Shuo Zheng; Xue Gong; Hongmei Ren; Zhuxin Li; Shuang Qu; Cheng Yu; Jining Yang; Pedro A Jose; Yundai Chen; Gengze Wu; Cuimei Hu; Junyi Yu; Chunyu Zeng
Journal:  Circulation       Date:  2022-08-25       Impact factor: 39.918

5.  Neat1 promotes acute kidney injury to chronic kidney disease by facilitating tubular epithelial cells apoptosis via sequestering miR-129-5p.

Authors:  Tongtong Ma; Hongwei Li; Hui Liu; Yili Peng; Tong Lin; Zhiya Deng; Nan Jia; Zhongqing Chen; Peng Wang
Journal:  Mol Ther       Date:  2022-05-26       Impact factor: 12.910

6.  Jian-Pi-Yi-Shen Formula Improves Adenine-Induced Chronic Kidney Disease via Regulating Tryptophan Metabolism and Aryl Hydrocarbon Receptor Signaling.

Authors:  Xinhui Liu; Ruyu Deng; Yulian Chen; Shiying Huang; Jiandong Lu; Lin Zheng; Guoliang Xiong; Shunmin Li
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

7.  Higher Neutrophil-To-Lymphocyte Ratio Was Associated with Increased Risk of Chronic Kidney Disease in Overweight/Obese but Not Normal-Weight Individuals.

Authors:  Chia-Ho Lin; Yu-Hsuan Li; Ya-Yu Wang; Wen-Dau Chang
Journal:  Int J Environ Res Public Health       Date:  2022-06-30       Impact factor: 4.614

8.  Red Blood Cell Distribution Width Is Associated With Adverse Kidney Outcomes in Patients With Chronic Kidney Disease.

Authors:  Xinwei Deng; Bixia Gao; Fang Wang; Ming-Hui Zhao; Jinwei Wang; Luxia Zhang
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 9.  MAFLD and CKD: An Updated Narrative Review.

Authors:  Alessandro Mantovani; Rosa Lombardi; Filippo Cattazzo; Chiara Zusi; Davide Cappelli; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

10.  ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway.

Authors:  Hui-Ting Wei; Yuan Xu; Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.